Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 57.1 kDa. The protein migrates as 80-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD117, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human CD117, His Tag (Cat. No. CD7-H52H4) is more than 90% and the molecular weight of this protein is around 75-100 kDa verified by SEC-MALS.
Immobilized Human CD117, His Tag (Cat. No. CD7-H52H4) at 2 μg/mL (100 μL/well) can bind Biotinylated Human SCF, Avitag,His Tag (Cat. No. SCF-H82E1) with a linear range of 0.5-8 ng/mL (QC tested).
Biotinylated Human SCF, Avitag,His Tag (Cat. No. SCF-H82E1) captured on Biotin CAP-Series S Sensor Chip can bind Human CD117, His Tag (Cat. No. CD7-H52H4) with an affinity constant of 0.236 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Thyroid Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Medullary thyroid cancer (MTC); Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
Imatinib mesylate | CGP-57148B; CGP-57148; STI-571; QTI-571; CTI-571; VR325; AER-901; YD-312; TNX-201 | Approved | Novartis Pharma Ag | glivic, 格列卫, Gleevec, Ruvise, Glivec, Gleevec/Glivec | EU | Leukemia, Myelogenous, Chronic | Novartis Europharm Ltd | 2001-05-10 | Diabetes Mellitus, Type 1; Hypereosinophilic Syndrome; Leukemia; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Ovarian Neoplasms; Solid tumours; Hypertension, Pulmonary; Hematopoietic stem cell transplantation (HSCT); Neoplasm, Residual; Skin Melanoma; Hematologic Neoplasms; Genital Diseases, Male; Ovarian germ cell tumor; Fibrosarcoma; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid, Accelerated Phase; Loiasis; Rhinitis, Allergic, Seasonal; Polycythemia Vera; Genital Neoplasms, Male; Abdominal Neoplasms; Leukemia, Hairy Cell; Histiocytoma, Malignant Fibrous; Desmoplastic Small Round Cell Tumor; Rectal Neoplasms; Stomach Neoplasms; Myeloproliferative Disorders; Skin Neoplasms; Leukemia, Myelomonocytic, Chronic; Coronavirus Disease 2019 (COVID-19); Scleroderma, Systemic; Graft vs Host Disease; Dermatofibrosarcoma; Liver Cirrhosis; Neoplasms; Neurofibromatoses; Mastocytosis, Systemic; Idiopathic Pulmonary Fibrosis; Myelodysplastic Syndromes; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma | Details |
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Avapritinib | BLU-285; CS-3007 | Approved | Blueprint Medicines Corp | Ayvakit, Ayvakyt, 泰吉华, Taijihua | United States | Gastrointestinal Stromal Tumors | Blueprint Medicines Corp | 2020-01-09 | Solid tumours; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Mastocytosis, Systemic; Central Nervous System Neoplasms; Leukemia, Mast-Cell; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Adenocarcinoma | Details |
Vorolanib | CM-082; X-82; EYP-1901 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Melanoma; Carcinoma, Non-Small-Cell Lung; Diabetic Retinopathy; Macular Degeneration; Carcinoma, Hepatocellular; Choroidal Neovascularization; Adenocarcinoma; Eye Diseases; Leukemia, Myeloid, Acute; Retinal Degeneration; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms | Details |
Ripretinib | DCC-2618 | Approved | Deciphera Pharmaceuticals | Qinlock, 擎乐 | United States | Gastrointestinal Stromal Tumors | Deciphera Pharmaceuticals Llc | 2020-05-15 | Mastocytosis, Systemic; Neoplasms; Gastrointestinal Stromal Tumors | Details |
Olverembatinib | D-824; GZD-824; APG-1351; GIBH-824; HQP-1351 | Approved | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | 耐立克 | Mainland China | Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase | Guangzhou Shunjian Biomedical Technology Co Ltd | 2021-11-25 | Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Solid tumours; Leukemia, Myeloid; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Gastrointestinal Stromal Tumors | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Common Bile Duct Neoplasms; Leukemia, Myeloid, Accelerated Phase; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Hematologic Neoplasms; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Solid tumours; Leukemia | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
Dasatinib Hydrate | BMS-354825; XS-004; NSC-732517 | Approved | Bristol-Myers Squibb Company | Spraysel, 施达赛, Dasynoc, Spricel, Sprycel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leukemia; Liver Neoplasms; Hematologic Neoplasms; Hypereosinophilic Syndrome; Solid tumours; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Bone metastases; Skin Melanoma; Rhabdomyosarcoma; Chondrosarcoma; Immunoproliferative Small Intestinal Disease; Ovarian Neoplasms; Leukemia, Myeloid; Cystadenocarcinoma; HIV Infections; Rectal Neoplasms; Polycythemia Vera; Leukemia, Lymphoid; Leukemia, Hairy Cell; Hormone-Resistant Prostate Neoplasms; Idiopathic Pulmonary Fibrosis; Colonic Neoplasms; Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Scleroderma, Systemic; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Mastocytosis, Systemic; Leukemia-Lymphoma, Adult T-Cell; Hodgkin Disease; Carcinoma, Verrucous; Lymphoma, Large-Cell, Immunoblastic; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (C | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Metastatic breast cancer; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Neurofibroma, Plexiform; Neurofibrosarcoma; Giant Cell Tumors; Sarcoma; Giant Cell Tumor of Tendon Sheath; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pancreatic Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Synovitis, Pigmented Villonodular; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Solid tumours | Details |
Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Osteosarcoma; Germinoma; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Uterine Cervical Diseases; Genital Neoplasms, Female; Gliosarcoma; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Chondrosarcoma, Extraskeletal Myxoid; Lung Neoplasms; Nasopharyngeal Carcinoma; Medullary thyroid cancer (MTC); Brain Neoplasms; Urethral Neoplasms; Psoriasis; Gastrinoma; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Neoplasms, Germ Cell and Embryonal; von Hippel-Lindau Disease; Thyroid Cancer, Papillary; Neoplasm Metastasis; Breast Neoplasms, Male; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Paraganglioma; Melanoma; Macular Degeneration; Carcinoma, Hepatocellular; Sarcoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Choriocarcinoma; Uterine Neoplasms; Lymphoma; Carcinoma, Neuroendocrine; Glioma; Carcinoma, Embryonal; Skin Melanoma; Neoplasms; Herpes Genitalis; Hemangiosarcoma; Squamous Cell Carcinoma of Head and Neck; Insulinoma; Pheochromo | Details |
Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Rhabdomyosarcoma; Solid tumours; Ovarian Neoplasms; Fibromatosis, Aggressive; Kidney Neoplasms; Leukemia, Myeloid; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Islet Cell; Insulinoma; Vipoma; Hemangiosarcoma; Esophageal Neoplasms; Wilms Tumor; Hypertension, Portal; Thyroid Carcinoma, Anaplastic; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Lymphomatoid Granulomatosis; Carcinoma, Transitional Cell; Colonic Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Endocrine Neoplasia Type 2a; Lymphoma, Large-Cell, Immunoblastic; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, | Details |
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Barzolvolimab | CDX-0159 | Phase 3 Clinical | Yale University, University Of Toronto - St. George Campus | Chronic Urticaria; Prurigo Nodularis; Skin Diseases; Eosinophilic Esophagitis; Urticaria; Dermatitis, Atopic | Details |
Seralutinib | GB-002; PK-10571 | Phase 3 Clinical | Gilead Sciences Inc | Pulmonary Arterial Hypertension | Details |
Chiauranib | CS-2164; CS2164 | Phase 3 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Ovarian Neoplasms; Solid tumours; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Carcinoma, Hepatocellular | Details |
Bezuclastinib | PLX-9486; CGT-9486 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Hematologic Neoplasms; Mastocytosis, Systemic; Leukemia, Mast-Cell; Gastrointestinal Stromal Tumors; Neoplasm Metastasis; Mastocytosis | Details |
oral enteric coated imatinib (Tenax Therapeutics) | TNX-201 (Tenax Therapeutics) | Phase 3 Clinical | PH Precision Med | Pulmonary Arterial Hypertension | Details |
Sitravatinib | MGCD-516; IND-155305; MGCD-0516; MG-91516; MG-516 | Phase 3 Clinical | Mirati Therapeutics Inc | Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Endometrial Neoplasms; Lung Neoplasms; Metastatic breast cancer; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Carcinoma, Squamous Cell; Hepatic Insufficiency; Ureteral Neoplasms; Solid tumours; Lung Diseases; Liposarcoma; Uveal melanoma; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Kidney Neoplasms; Biliary Tract Neoplasms | Details |
Elenestinib | BLU-263 | Phase 3 Clinical | Blueprint Medicines Corp | Mastocytosis, Systemic; Mastocytosis | Details |
Autologous Human C-Kit Cardiac Stem Cells (CSCs) II (ISCI / University of Miami Miller School of Medicine) | Phase 2 Clinical | University Of Miami, Elpiscience (Shanghai) Biopharma Ltd | Myocardial Infarction; Ventricular Dysfunction, Left | Details | |
Telatinib | EOC-315; BAY-57-9352 | Phase 2 Clinical | Bayer AG | Solid tumours; Stomach Neoplasms | Details |
Briquilimab | AMG-191; JSP-191; JSP191 | Phase 2 Clinical | Amgen Inc, National Heart, Lung And Blood Institute, Stanford University | Chronic Urticaria; Myelodysplastic Syndromes; Severe Combined Immunodeficiency; Asthma; Leukemia, Myeloid, Acute; Granulomatous Disease, Chronic; Immunologic Deficiency Syndromes; Anemia, Sickle Cell | Details |
DCC-3009 | DCC-3009 | Phase 2 Clinical | Deciphera Pharmaceuticals Inc | Gastrointestinal Stromal Tumors | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
Opelkibart elmanitin | MGTA-117 | Phase 2 Clinical | Heidelberg Pharma AG | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Lymphoma; Diagnostic agents; Melanoma | Details |
Tafetinib Malate | SIM-0702; SIM-1005; SIM-010603 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, Nanjing Yoko Biomedical Co Ltd, Jilin Boda Pharmaceutical Co Ltd | Neoplasms | Details |
Amorphous Formulation of Sorafenib in Mesoporous Magnesium Carbonate | DPH001; DPH-001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
THB-335 | THB-335; THB335 | Phase 1 Clinical | Third Harmonic Bio | Inflammation | Details |
CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Fibrosis; Inflammation; Hypersensitivity | Details |
QX-013N | QX-013-N; QX013N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Chronic Urticaria; Urticaria | Details |
NN-2101 | NN-2101 | Phase 1 Clinical | Novelty Nobility Inc | Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
NN-3201 | NN-3201 | Phase 1 Clinical | Novelty Nobility Inc | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Uveal melanoma; Neuroendocrine Tumors; Carcinoma, Adenoid Cystic; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute | Details |
THB-001 | THB-001 | Phase 1 Clinical | Novartis Corp | Gastrointestinal Diseases; Chronic Urticaria; Respiratory Tract Diseases | Details |
T-1301 | T-1301; DBPR-216 | Phase 1 Clinical | Taivex Therapeutics Corp | Solid tumours; Lymphoma | Details |
GS-0174 | GS-0174 | Phase 1 Clinical | Forty Seven Inc | Hematologic Neoplasms | Details |
TR-64 | TR-64 | Phase 1 Clinical | Tarapeutics Science Inc | Solid tumours; Gastrointestinal Stromal Tumors | Details |
AZD-3229 | NB-003; NB003; AZD-3229; AZD3229 | Phase 1 Clinical | Astrazeneca Turkey | Solid tumours; Gastrointestinal Stromal Tumors; Influenza B virus infection | Details |
AGX-0073 | AGX-0073 | Phase 1 Clinical | Shanghai Aojian Biological Technology Co Ltd | Solid tumours | Details |
Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
This web search service is supported by Google Inc.